Epithelioid Sarcoma Clinical Trial
Official title:
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
NCT number | NCT04225429 |
Other study ID # | EZH-801 |
Secondary ID | |
Status | No longer available |
Phase | |
First received | |
Last updated |
Verified date | March 2024 |
Source | Ipsen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Status | No longer available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Patients with epithelioid sarcoma (ES) are eligible to enroll in the EAP. The patient with ES must have an advanced disease that is considered life threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions other than ES are not eligible for the tazemetostat EAP. Inclusion Criteria: 1. Age (at the time of consent): =18 years of age. 2. They are unable to participate in tazemetostat clinical trials for their condition. 3. Can provide signed written informed consent. 4. Morphology and immunophenotypic panel consistent with epithelioid sarcoma (e.g., CD34, epithelial embrane antigen [EMA], Keratin, and INI1). 5. Female patients of childbearing potential should: - Agree to practice one highly effective method of contraception and one additional effective barrier method (eg, condom or diaphragm with spermicide) at the same time, from the time of providing voluntary written informed consent through 30 days or 5 half-lives (whichever is longer) after the last dose of tazemetostat, and - Have a negative beta-human chorionic gonadotropin (ß-hCG) pregnancy test at time of screening and within 14 days prior to planned first dose of tazemetostat (urine or serum test is acceptable however, positive urine tests must be confirmed with serum testing), and - Agree to use effective contraception from start of screening until 30 days following the last dose of tazemetostat and have a male partner who uses a condom, or - Practice true abstinence, (when this is in line with the preferred and usual lifestyle of the patient) or - Have a male partner who is vasectomized. 6. Male patients with a female partner of childbearing potential should: - Be vasectomized, or - Agree to use condoms from at least 7 days prior to initiating and during tazemetostat treatment and for at least 30 days following the last dose of tazemetostat, or - Have a female partner who is NOT of childbearing potential. Exclusion Criteria: - 1. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment while on the EAP. 2. Is currently taking any prohibited medication(s) as described in Section 6.3 of the protocol. 3. Has known hypersensitivity to any of the components of tazemetostat or other inhibitor(s) of EZH2. 4. Has thrombocytopenia, neutropenia, or anemia of Grade =3 (per CTCAE v5.0 criteria) within the past month, or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS). 5. Is known to have any abnormalities associated with MDS (e.g. del 5q, chr 7 abn) and MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing. 6. Has a prior history of T-LBL/T-ALL. 7. For female patients of childbearing potential: Is pregnant or nursing. 8. For male patients: Is unwilling to adhere to contraception criteria from at least 7 days prior to initiating and during tazemetostat treatment and for at least 30 days after last dose of tazemetostat. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Epizyme, Inc. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT05286801 -
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT03069378 -
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03837678 -
Epithelioid Sarcoma Natural History Study
|
||
Active, not recruiting |
NCT02180867 -
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
|
Phase 2/Phase 3 | |
Recruiting |
NCT04008238 -
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
|
N/A | |
Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT02601950 -
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT03190174 -
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT03099681 -
An Observational Study on Epithelioid Sarcoma
|
||
Recruiting |
NCT04416568 -
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
|
Phase 2 | |
Recruiting |
NCT05407441 -
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03967834 -
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
|
N/A |